<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">36985581</article-id><article-id pub-id-type="pmc">PMC10053799</article-id>
<article-id pub-id-type="doi">10.3390/molecules28062609</article-id><article-id pub-id-type="publisher-id">molecules-28-02609</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Luteolin 4&#x02032;-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3179-3352</contrib-id><name><surname>El-Shiekh</surname><given-names>Riham A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-molecules-28-02609" ref-type="aff">1</xref><xref rid="c1-molecules-28-02609" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Elhemely</surname><given-names>Mai A.</given-names></name><xref rid="af2-molecules-28-02609" ref-type="aff">2</xref><xref rid="af3-molecules-28-02609" ref-type="aff">3</xref><xref rid="c1-molecules-28-02609" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5923-1466</contrib-id><name><surname>Naguib</surname><given-names>Ibrahim A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af4-molecules-28-02609" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6002-9249</contrib-id><name><surname>Bukhari</surname><given-names>Sarah I.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af5-molecules-28-02609" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5381-0037</contrib-id><name><surname>Elshimy</surname><given-names>Rana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af6-molecules-28-02609" ref-type="aff">6</xref><xref rid="af7-molecules-28-02609" ref-type="aff">7</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Martins</surname><given-names>Carlos H. G.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-28-02609"><label>1</label>Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr el Aini St., Cairo 11562, Egypt</aff><aff id="af2-molecules-28-02609"><label>2</label>School of Medical Sciences, Faculty of Biology, Medicine &#x00026; Health, The University of Manchester, Manchester M20 4GJ, UK</aff><aff id="af3-molecules-28-02609"><label>3</label>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt</aff><aff id="af4-molecules-28-02609"><label>4</label>Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia; <email>i.abdelaal@tu.edu.sa</email></aff><aff id="af5-molecules-28-02609"><label>5</label>Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; <email>sbukhari@ksu.edu.sa</email></aff><aff id="af6-molecules-28-02609"><label>6</label>Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, Giza 12451, Egypt; <email>rana.elshimy@acu.edu.eg</email></aff><aff id="af7-molecules-28-02609"><label>7</label>Department of Microbiology and Immunology, Egyptian Drug Authority, Giza 12511, Egypt</aff><author-notes><corresp id="c1-molecules-28-02609"><label>*</label>Correspondence: <email>riham.adel@pharma.cu.edu.eg</email> (R.A.E.-S.); <email>mai.ali@manchester.ac.uk</email> (M.A.E.)</corresp></author-notes><pub-date date-type="update" publication-format="electronic"><day>13</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>28</volume><issue>6</issue><elocation-id>2609</elocation-id><history><date date-type="received"><day>06</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>05</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>06</day><month>3</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Multidrug resistance (MDR) pathogens are usually associated with higher morbidity and mortality rates. Flavonoids are good candidates for the development of new potential antimicrobials. This research investigated whether luteolin 4&#x02032;-neohesperidoside (L4N) has antibacterial and synergistic activities against four antibiotic-resistant pathogens: methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA), <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">fos</italic>A-positive shiga toxin producing the <italic toggle="yes">Escherichia coli</italic> serogroup O111 (STEC O111), and <italic toggle="yes">Bacillus cereus</italic>. In vitro antimicrobial susceptibility testing revealed highly potent anti-MRSA (MIC of 106.66 &#x000b1; 6.95 &#x000b5;g/mL), anti-<italic toggle="yes">K. pneumoniae</italic> (MIC of 53.33 &#x000b1; 8.47 &#x000b5;g/mL) and anti-STEC O111 (MIC of 26.66 &#x000b1; 5.23 &#x000b5;g/mL) activities. Significant synergistic combination was clearly noted in the case of gentamycin (GEN) against Gram-negative bacteria. In the case of <italic toggle="yes">B. cereus</italic>, the combination of vancomycin (VAN) with L4N could efficiently inhibit bacterial growth, despite the pathogen being VAN-resistant (MIC of 213.33 &#x000b1; 7.9 &#x000b5;g/mL). In vivo evaluation of L4N showed significant decreases in <italic toggle="yes">K. pneumoniae</italic> and STEC shedding and colonization. Treatment could significantly diminish the levels of pro-inflammatory markers, tumor necrosis factor-alpha (TNF-&#x003b1;), and immunoglobulin (IgM). Additionally, the renal and pulmonary lesions were remarkably enhanced, with a significant decrease in the bacterial loads in the tissues. Finally, this study presents L4N as a potent substitute for traditional antibiotics with anti-STEC O111 and anti-<italic toggle="yes">K. pneumoniae</italic> potential, a finding which is reported here for the first time.</p></abstract><kwd-group><kwd>STEC O111</kwd><kwd><italic toggle="yes">K. pneumoniae</italic></kwd><kwd>antimicrobial resistance</kwd><kwd>luteolin 4&#x02032;-neohesperidoside</kwd><kwd>flavonoids</kwd><kwd>antibacterial</kwd></kwd-group><funding-group><award-group><funding-source>King Saud University</funding-source><award-id>RSP2023R497</award-id></award-group><funding-statement>This research was supported by the Researchers Supporting Project, number RSP2023R497, funded by King Saud University, Riyadh, Saudi Arabia.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-28-02609"><title>1. Introduction</title><p>In 2018, the World Health Organization (WHO) stated that the number of antibiotic-resistant pathogenic bacteria had drastically risen to reach a high-risk level that required global cooperation. More than 2.8 million people are infected with antibiotic-resistant bacteria every year in the United States, with about 35,000 dying as a result [<xref rid="B1-molecules-28-02609" ref-type="bibr">1</xref>]. These superbugs are expanding globally, and the endless emergence of new resistance mechanisms challenges our ability to treat common infectious diseases and some nosocomial infections. The major trigger behind this crisis is the misuse of limited antibiotic sources in humans and animals. Likewise, the rate of new antibiotic development does not meet the growing rate of resistance.</p><p>Consequently, in addition to enhancing general awareness of proper antibiotic use, the search for novel antibiotics should be a priority for many research groups in the field of drug discovery [<xref rid="B2-molecules-28-02609" ref-type="bibr">2</xref>]. It is worth noting that different classes of natural products, such as steroids, alkaloids, terpenoids, flavonoids, anthraquinone, tannins, saponins, etc., have been recommended to tackle the multidrug-resistant bacterial strains due to their potential pharmacological effects [<xref rid="B3-molecules-28-02609" ref-type="bibr">3</xref>]. Most of the commonly used antibiotics are derived from microbial sources, while the plant-based ones have generally been utilized in recent years, during which several potential candidates have shown promising actions that can be further established and translated into clinical therapeutics [<xref rid="B4-molecules-28-02609" ref-type="bibr">4</xref>].</p><p>Flavonoids are a large group of phytocompounds with different structures. As a main dietary component, flavonoids are reported to have health-promoting activities due to their high antioxidant capacity in both in vivo and in vitro models. They can be used in the management of degenerative diseases such as cardiovascular diseases, cancers, and other age-related diseases [<xref rid="B5-molecules-28-02609" ref-type="bibr">5</xref>]. This is in addition to their protective effects against many infections (bacterial and viral diseases), such as those found in honey and propolis. They are reported to be largely responsible for this plant&#x02019;s antimicrobial effects, with a strong background of use in clinical trials as antibiotics alone or in combination with conventional antibiotics [<xref rid="B6-molecules-28-02609" ref-type="bibr">6</xref>,<xref rid="B7-molecules-28-02609" ref-type="bibr">7</xref>].</p><p>Several studies have demonstrated the antibacterial effects of flavonoid-rich extracts and pure flavonoids. Luteolin (flavones) isolated from plants showed promising antibacterial activities against STEC O111, MRSA, <italic toggle="yes">K. pneumoniae</italic>, and <italic toggle="yes">B. cereus</italic> [<xref rid="B8-molecules-28-02609" ref-type="bibr">8</xref>].</p><p>Luteolin-4&#x02032;-<italic toggle="yes">O</italic>-neohesperidoside (L4N), i.e., luteolin-4&#x02032;-<italic toggle="yes">O</italic>-[&#x003b1;-(L-rhamnopyranosyl-(1&#x02192;2)-<italic toggle="yes">&#x003b2;</italic>-D-glucopyranoside)], was previously isolated from the genus <italic toggle="yes">Caralluma</italic>, showing significant anti-inflammatory and antinociceptive actions [<xref rid="B9-molecules-28-02609" ref-type="bibr">9</xref>], and it also showed antibiofilm activity against an MRSA skin infection model [<xref rid="B10-molecules-28-02609" ref-type="bibr">10</xref>]. Luteolin showed potent antimicrobial activity against <italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. pneumoniae</italic>, MRSA, <italic toggle="yes">Trueperella pyogenes</italic>, and <italic toggle="yes">Mycobacterium tuberculosis</italic>. In addition, luteolin-7-<italic toggle="yes">O</italic>-&#x003b2;-D-glucuronide was reported to have potential activity against Gram-negative bacteria [<xref rid="B11-molecules-28-02609" ref-type="bibr">11</xref>,<xref rid="B12-molecules-28-02609" ref-type="bibr">12</xref>,<xref rid="B13-molecules-28-02609" ref-type="bibr">13</xref>,<xref rid="B14-molecules-28-02609" ref-type="bibr">14</xref>]. Additionally, flavones such as luteolin were found to strongly reduce <italic toggle="yes">E. coli</italic> macro-colony biofilms [<xref rid="B8-molecules-28-02609" ref-type="bibr">8</xref>,<xref rid="B15-molecules-28-02609" ref-type="bibr">15</xref>]. Thus, our study was designed to document the benefacial effects of flavones so as to combat resistant bacteria.</p><p>STEC is one of the pathogenic <italic toggle="yes">E. coli</italic> strains, among which certain strains have been found to be more virulent to humans, especially those belonging to serogroups O111 and O157. In this context, STEC O111 is a major public health concern in both developed and developing countries [<xref rid="B3-molecules-28-02609" ref-type="bibr">3</xref>]. Enterohemorrhagic patients infected with STEC O111 are at a high risk of developing life-threatening extraintestinal complications, such as hemolytic uremic syndrome, hemorrhagic cystitis, and acute renal failure [<xref rid="B4-molecules-28-02609" ref-type="bibr">4</xref>].</p><p>For uncomplicated cystitis caused by STEC, the main first-line empirical treatment is fosfomycin [<xref rid="B16-molecules-28-02609" ref-type="bibr">16</xref>]. Fosfomycin is a broad-spectrum bactericidal antibiotic and among the most active agents used for sparing carbapenems in extended-spectrum b-lactamase (ESBL)-producing isolates and the treatment of carbapenem-resistant Enterobacteriaceae in combination with colistin [<xref rid="B17-molecules-28-02609" ref-type="bibr">17</xref>]. The treatment of UTIs caused by STEC O111 is freuqnetly hindered by fosfomycin resistance, which emerges via the production of <italic toggle="yes">fos</italic>-A, a glutathione S-transferase that inactivates fosfomycin through the addition of a glutathione residue [<xref rid="B18-molecules-28-02609" ref-type="bibr">18</xref>].</p><p><italic toggle="yes">K. pneumoniae</italic> is a Gram-negative bacterium that causes pneumonia, intra-abdominal and blood infections, meningitis, pyogenic liver abscesses, and prominent nosocomial infections, with high mortality and morbidity rates in hospitalized and immunocompromised patients [<xref rid="B5-molecules-28-02609" ref-type="bibr">5</xref>]. The expansion of multidrug-resistant (MDR) <italic toggle="yes">K. pneumoniae</italic> has resulted in an urgent need for the development of new, potent antimicrobial agents [<xref rid="B6-molecules-28-02609" ref-type="bibr">6</xref>].</p><p><italic toggle="yes">B. cereus</italic>, a volatile human pathogen, is an etiological negotiator of localized wounds; anthrax-like progressive pneumonia; intestinal, non-intestinal, and ocular infections; fulminant sepsis; and an overwhelming number of central nervous system infections, predominantly in immunosuppressed individuals and neonates [<xref rid="B7-molecules-28-02609" ref-type="bibr">7</xref>,<xref rid="B8-molecules-28-02609" ref-type="bibr">8</xref>].</p><p>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) is a prominent agent of community- and health-care-associated infections (CAIs and HAIs) [<xref rid="B9-molecules-28-02609" ref-type="bibr">9</xref>], ranging from superficial soft tissue infections (SSTI) to toxic shock syndrome (TSS), sepsis, and death [<xref rid="B10-molecules-28-02609" ref-type="bibr">10</xref>].</p><p>The rise in resistance to various classes of antibiotics among the previously mentioned strains is a troublesome challenge faced by healthcare providers and hospital infection control units worldwide. The SARS-CoV-2 pandemic had crucial impacts on global health and economies [<xref rid="B11-molecules-28-02609" ref-type="bibr">11</xref>]. In addition, it lent credence to the need to develop novel antimicrobials to be used solely or combined with traditional antibiotics. This study aimed to investigate the antimicrobial potential of luteolin 4&#x02032;-neohesperidoside, L4N (<xref rid="molecules-28-02609-f001" ref-type="fig">Figure 1</xref>), against four MDR clinical isolates via in vitro and in vivo assessments.</p></sec><sec sec-type="results" id="sec2-molecules-28-02609"><title>2. Results</title><p>Flavonoids play an important role in decreasing the risk of several diseases associated with a diet rich in plant-derived foods. They are also common phytoconstituents used in traditional medicine for the treatment of a wide range of diseases. The emergence of multidrug resistance (MDR) and extensive drug resistance (XDR) among clinical isolates poses a significant challenge to conventional antibiotics, creating the antimicrobial resistance (AMR) crisis. In our study, we isolated a compound identified as luteolin 4&#x02032;-neohesperidoside (L4N) and investigated its effects against resistant strains.</p><sec id="sec2dot1-molecules-28-02609"><title>2.1. Spectral Data</title><sec><title>Compound <bold>L4N</bold> (CD<sub>3</sub>OD)</title><p><sup>1</sup>HNMR; 6.63 (s, H3), 6.23 (d, J = 2.2 Hz, H6), 6.47 (d, J = 2.2 Hz, H8), 7.49 (d, <italic toggle="yes">J</italic> = 2.2, 8.8 Hz, H2&#x02032;), 7.46 (dd, <italic toggle="yes">J</italic> = 2.2, 8.8 Hz, H5&#x02032;), 7.28 (d, J = 8.8 Hz, H6&#x02032;), 5.21 (s, H1&#x02033;), 5.29 (d, j = 1.8 Hz, H2&#x02033;), 4.58 (s, H1&#x02034;), 3.17&#x02013;4.02 (m, sugars).</p><p><sup>13</sup>CNMR; 164.34 (C1&#x00026;10), 103.86 (C2), 182.49 (C3), 158.47 (C4), 101.86 (C5), 162.77 (C6), 93.75 (C7), 137.47 (C8), 104.12 (C9), 125.86 (C1&#x02032;), 116.39 (C2&#x02032;), 148.31 (C3&#x02032;), 147.76 (C4&#x02032;), 113.61 (C5&#x02032;), 118.72 (C5&#x02032;), 101.74 (C1&#x02033;), 79.57 (C2&#x02033;), 77.21 (C3&#x02033;), 70.82 (C4&#x02033;), 76.76 (C5&#x02033;), 60.82 (C6&#x02033;), 99.48 (C1&#x02034;), 70.84 (C2&#x02034;), 72.58 (C3&#x02034;), 69.18 (C4&#x02034;), 69.78 (C5&#x02034;), 16.46 (C6&#x02034;) [<xref rid="B19-molecules-28-02609" ref-type="bibr">19</xref>].</p></sec></sec><sec id="sec2dot2-molecules-28-02609"><title>2.2. In Vitro Study</title><p>L4N showed inhibition zones of 20.6 &#x000b1; 2.08 mm and 18.00 + 0 mm against STEC 0111 and <italic toggle="yes">K. pneumoniae</italic>, respectively, which are far higher than those of AK and GEN, being 0.0 &#x000b1; 0.0 and 17.0 &#x000b1; 1.00 mm, respectively. This indicates the promising antimicrobial activity of the compound (<xref rid="molecules-28-02609-t001" ref-type="table">Table 1</xref>). There were highly significant differences between groups in the results for the inhibition zones of the antibiotics and L4N in regard to the MDR Gram-negative bacteria (MDR <italic toggle="yes">K. pneumoniae</italic> and STEC O111).</p><p>On the other hand, for the Gram-positive bacteria, L4N exhibited inhibition zones of 19.0 &#x000b1; 0 mm and 6.0 &#x000b1; 1.0 mm against MRSA and MDR <italic toggle="yes">B. cereus</italic>, respectively (<xref rid="molecules-28-02609-t002" ref-type="table">Table 2</xref>). There were highly significant differences between groups in the results for the inhibition zones of the antibiotics and L4N in regard to the MDR Gram-positive bacteria (MDR <italic toggle="yes">B. cereus</italic> and MRSA) at a <italic toggle="yes">p</italic> value &#x02264; 0.05.</p><p>A potent synergistic effect was noticed upon the combination of L4N with GEN against STEC and with VAN against MRSA and <italic toggle="yes">B. cereus</italic>, which was resistant to L4N, and for VAN used solely (<xref rid="molecules-28-02609-f002" ref-type="fig">Figure 2</xref>). These results agree with Amin et al. [<xref rid="B20-molecules-28-02609" ref-type="bibr">20</xref>], who reported luteolin&#x02019;s synergistic effect when combined with ceftriaxone and imipenem, ampicillin, oxacillin, and GEN against MRSA.</p><p>The MIC values of L4N against the tested Enterobacteriaceae were 26.66 &#x000b5;g/mL for STEC and 53.33 &#x000b5;g/mL for MDR <italic toggle="yes">K. pneumoniae</italic> (<xref rid="molecules-28-02609-t003" ref-type="table">Table 3</xref>). </p><p>The samples showed lower activity against the Gram-positive strains, with MIC values of 106.66 &#x003bc;g/mL and 213.33 &#x003bc;g/mL against MRSA and B. cereus, respectively (<xref rid="molecules-28-02609-t004" ref-type="table">Table 4</xref>).</p></sec><sec id="sec2dot3-molecules-28-02609"><title>2.3. In Vivo Study</title><p>In this study, a model of <italic toggle="yes">K. pneumoniae</italic>-induced sepsis and germ-free mouse models were used to evaluate the antimicrobial activities of L4N against <italic toggle="yes">K. pneumoniae</italic> and STEC O111, respectively. When performing the in vivo assessment, both positive control groups died before the end of the experiment. Postmortem testing confirmed that all the mice were infected with high CFU loads, indicating that their death was caused by infection.</p><p>The levels of tumor necrosis factor-alpha (TNF-&#x003b1;) and immunoglobulin M (IgM) were assessed to determine whether <italic toggle="yes">E. coli</italic> and <italic toggle="yes">K. pneumoniae</italic> strains elicited a proinflammatory environment and to conduct a comparison between the positive control groups, which were untreated, and the groups treated with either GEN or L4N. All the mice treated with L4N showed normal values of TNF-&#x003b1; and IgM (<xref rid="molecules-28-02609-f003" ref-type="fig">Figure 3</xref> and <xref rid="molecules-28-02609-f004" ref-type="fig">Figure 4</xref>).</p><p>The lungs of the <italic toggle="yes">K. pneumoniae</italic> (<xref rid="molecules-28-02609-f005" ref-type="fig">Figure 5</xref>a&#x02013;c)-positive control mice showed dilated pulmonary blood vessels and focal hemorrhages in the interstitial tissue, as well as the alveolar lamina. Inflammatory infiltrate composed of histiocytes and polymorphonuclear cells was also detected. On the other hand, lungs of the mice infected with <italic toggle="yes">K. pneumoniae</italic> and then treated with Luteolin showed moderate infiltration of inflammatory cells, and emphysema of the pulmonary alveoli were observed. Lungs of the mice infected with <italic toggle="yes">K. pneumoniae</italic> and then treated with GEN showed emphysema of the pulmonary alveoli and mild inflammatory cell infiltration in the pulmonary tissues. In the group treated with luteolin, the scoring of the histopathological lesions (<xref rid="molecules-28-02609-t005" ref-type="table">Table 5</xref>) revealed no signs of hemorrhage, no RBCs in the alveolar lamina, and no perivascular oedema.</p><p>After 24 h of <italic toggle="yes">K. pneumoniae</italic> inoculation, the mice showed signs of faster respiration, lower activity, disordered bristle or coats, and increased secretion around the eyes. These symptoms were enhanced after 48 h of inoculation, and the mice began to die. All the mice died within 168 h (7 days) in the model group, indicating that KNP inoculation induces a severe pulmonary inflammatory response, while in the L4N-treated group, pulmonary hemorrhage and the interalveolar thickness were remarkably reduced.</p><p>In the kidneys of the mice infected with STEC O111 (<xref rid="molecules-28-02609-f006" ref-type="fig">Figure 6</xref>a&#x02013;c) (positive control group), the appearance of vacuoles of variable sizes in the cytoplasm of the tubular epithelium indicated necrotic changes. Moreover, characteristic histopathological changes, including coagulation necrosis with karyopyknotic nuclei, were also observed. However, the kidneys of mice infected with STEC and then treated with L4N showed interstitial inflammatory cell infiltration. Similarly, the kidneys of mice infected with STEC and then treated with GEN revealed focal inflammatory cell infiltration in the renal interstitial tissues and degenerative changes in the renal tubular epithelium. The scoring of histopathological lesions (<xref rid="molecules-28-02609-t006" ref-type="table">Table 6</xref>) revealed that the mice treated with L4N showed no subcapsular hemorrhages, interstitial hemorrhages, necrobiotic changes in the tubular epithelium, interstitial inflammatory cell infiltration, or renal casts.</p><p>For the quantification of bacterial shedding, the bacteria in the feces were counted. The fecal count of STEC in the mice feces was reduced from 2 &#x000d7; 10<sup>7</sup> to 3 &#x000d7; 10<sup>2</sup> after 10 days of treatment with L4N, while that of the GEN-treated mice was reduced from 1 &#x000d7; 10<sup>7</sup> to 4 &#x000d7; 10<sup>3</sup> (<xref rid="molecules-28-02609-f007" ref-type="fig">Figure 7</xref> and <xref rid="molecules-28-02609-f008" ref-type="fig">Figure 8</xref>). On the other hand, L4N and GEN could reduce the bacterial loads of <italic toggle="yes">K. pneumoniae</italic> from 19 &#x000d7; 10<sup>6</sup> to 5 &#x000d7; 10<sup>2</sup> and from 27 &#x000d7; 10<sup>6</sup> to &#x0003e;250 &#x000d7; 10<sup>2</sup>, respectively (<xref rid="molecules-28-02609-t007" ref-type="table">Table 7</xref>). The count of colonizing <italic toggle="yes">K. pneumoniae</italic> in the lungs and kidneys revealed a significant reduction in the bacterial count to 5 &#x000d7; 10<sup>1</sup> in the lungs and to total eradication in the kidneys.</p></sec></sec><sec sec-type="discussion" id="sec3-molecules-28-02609"><title>3. Discussion</title><p>The World Health Organization (WHO) has defined the fight against AMR as a priority and identified <italic toggle="yes">K. pneumoniae</italic> and <italic toggle="yes">E. coli</italic> as examples of critical, high-priority pathogens [<xref rid="B22-molecules-28-02609" ref-type="bibr">22</xref>]. Although both are normal examples of human bacteria, they can easily develop AMR. Moreover, resistance to ampicillin, chloramphenicol, colistin, ciprofloxacin, fosfomycin, gentamicin, nitrofurantoin, tetracycline, trimethoprim/sulfamethoxazole, cefazolin, cefuroxime, and tobramycin has been rapidly increasing during the past few years [<xref rid="B23-molecules-28-02609" ref-type="bibr">23</xref>].</p><p>Flavonoids, also known as polyphenolic compounds, have been widely tested for their antibacterial properties due to their ability to retard the growth of different pathogenic microorganisms, including MDR bacteria [<xref rid="B3-molecules-28-02609" ref-type="bibr">3</xref>]. They are more active against Gram-negative bacteria than Gram-positive bacteria, reflecting a selective activity against Gram-negative bacteria. In particular, the Enterobacteriaceae showed the greatest sensitivity to flavonoids, for which the MIC was reported to be between 4 and 2048 &#x003bc;g/mL [<xref rid="B24-molecules-28-02609" ref-type="bibr">24</xref>]. Our results presented herein collectively demonstrate that L4N effectively inhibits 0111 and <italic toggle="yes">K. pneumoniae</italic> infection in mice. The hydroxylation of C5, C7, C3&#x02032;, and C4&#x02032; has been widely reported to increase the bacterial inhibition of flavonoids [<xref rid="B3-molecules-28-02609" ref-type="bibr">3</xref>], and this finding is in agreement with our data. Furthermore, this is the first report on the role of L4N in the treatment of <italic toggle="yes">E. coli</italic> 0111 and MDR <italic toggle="yes">K. pneumoniae</italic>. The results obtained in the present study reveal the potent anti-<italic toggle="yes">K. pneumoniae</italic> and anti-STEC O111 effects of L4N. This observation is based on the results of a decreased bacterial burden and reduced level of the inflammatory mediator TNF-&#x003b1; and immunoglobulin (IgM).</p></sec><sec id="sec4-molecules-28-02609"><title>4. Materials and Methods</title><sec id="sec4dot1-molecules-28-02609"><title>4.1. Isolation of L4N from Phyllanthus Emblica</title><p>Dried fruits of <italic toggle="yes">P. emblica</italic> L. were obtained from a local market in Cairo, Egypt. The plants were kindly authenticated by Mrs. Therese Labib, Consultant of Plant Taxonomy at the Ministry of Agriculture and Former Director of El-Orman Botanical Garden. The dried plants (1 Kg) were ground and extracted using methyl alcohol by maceration for 3 days. To the concentrated alcoholic extract (150 g), 500 mL of water was added, and then the mixture was fractionated with dichloromethane (4 &#x000d7; 400 mL) and <italic toggle="yes">n</italic>-butyl alcohol (4 &#x000d7; 400 mL). A total of 20 grams of <italic toggle="yes">n</italic>-butyl alcohol extract was further subjected to polyamide chromatography (400 g of polyamide) by stepwise elution with aqueous methanol (0, 25, 50, 75 and 100%, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) to obtain five fractions. Fraction two (25% aqueous methanol) was evaporated to dryness under reduced pressure and yielded 750 mg. Then, the fraction was purified in a RP-18 silica gel column (1.5 &#x000d7; 25 cm) using MeOH: MeCN: H<sub>2</sub>O (7:3:0.5) to yield 130 mg of L4N, isolated as a yellow powder.</p></sec><sec id="sec4dot2-molecules-28-02609"><title>4.2. Characterization</title><p>NMR analysis was conducted on a Bruker High-Performance Avance III FTNMR spectrometer (<sup>1</sup>H-NMR: 400 MHz &#x00026; <sup>13</sup>C-NMR: 100 MHz) using TMS as the internal standard. Analytical TLC was performed on Merck TLC plates with KGF Silica gel 60 and KGF RP-18 Silica gel 60, Kenilworth, NJ, USA and the spots were visualized under UV light (254 &#x00026; 365 nm) after spraying with aluminum chloride. Column chromatography was carried out on flash silica gel 60 (Merck, Kenilworth, NJ, USA, particle size 230, 400 mesh), RP-C18 (silica gel, 40 &#x000d7; 10<sup>63</sup> mm; Merck, Kenilworth, NJ, USA), and polyamide (Merck, Kenilworth, NJ, USA).</p></sec><sec id="sec4dot3-molecules-28-02609"><title>4.3. Screening for Multidrug-Resistant Bacteria</title><p>On 5% blood agar plates, bacterial cultures were grown at 37 &#x000b0;C overnight, followed by inoculation on Mueller&#x02013;Hinton agar. The susceptibilities of the clinical isolates were determined according to the CLSI protocol guidelines for <italic toggle="yes">Enterobacteriaceae</italic> [<xref rid="B25-molecules-28-02609" ref-type="bibr">25</xref>]. The selected multidrug-resistant strains were screened for their resistance to more than two different classes of antibiotics following the disk diffusion method protocol (as in the CLSI guidelines) and WHO recommendations (CLSI, 2020; CLSI, 2014).</p></sec><sec id="sec4dot4-molecules-28-02609"><title>4.4. In Vitro Studies</title><p>The biological assay was carried out using previously phenotypically and genotypically identified bacterial strains, namely, multidrug-resistant STEC O111 and MRSA [<xref rid="B23-molecules-28-02609" ref-type="bibr">23</xref>,<xref rid="B26-molecules-28-02609" ref-type="bibr">26</xref>]. Multidrug-resistant <italic toggle="yes">Bacillus cereus</italic> and multidrug-resistant <italic toggle="yes">K. pneumoniae</italic> were isolated from the intensive care unit of a tertiary care center in Cairo [<xref rid="B27-molecules-28-02609" ref-type="bibr">27</xref>].</p><p>Different culture media were used for each bacterium for identification and antibiotic susceptivity testing, as described previously [<xref rid="B28-molecules-28-02609" ref-type="bibr">28</xref>]. TBX chromogenic agar media and MacConkey agar were used for the fecal counts of <italic toggle="yes">E. coli</italic> and <italic toggle="yes">K. pneumoniae</italic>, respectively [<xref rid="B27-molecules-28-02609" ref-type="bibr">27</xref>].</p><p>The antimicrobial activities of L4N were first screened for their inhibitory zones by the agar disc diffusion method [<xref rid="B26-molecules-28-02609" ref-type="bibr">26</xref>,<xref rid="B29-molecules-28-02609" ref-type="bibr">29</xref>]. As a positive control for Gram-negative bacteria, gentamycin 10 &#x000b5;g (GEN) and amikacin 30 &#x000b5;g (AK) were used, while vancomycin (VAN) 30 &#x000b5;g and penicillin (PEN) 10 &#x000b5;g were used for the Gram-positive bacteria. On the other hand, a disc infused with 0.2% DMSO was used as the negative control. To test for synergistic or antagonistic effects between our tested compound and traditional antibiotics, they were combined with the compound. The assay was repeated using L4N alone, antibiotics alone, or a combination of both. The plates were incubated at 37 &#x000b0;C for 24 h, whereafter the zones of growth inhibition around the discs were observed and measured (mm). The tests were performed in triplicate and repeated twice [<xref rid="B30-molecules-28-02609" ref-type="bibr">30</xref>,<xref rid="B31-molecules-28-02609" ref-type="bibr">31</xref>,<xref rid="B32-molecules-28-02609" ref-type="bibr">32</xref>] (CLSI, 2018, 2020).</p><p>The microbroth dilution method was implemented to determine the MIC [<xref rid="B22-molecules-28-02609" ref-type="bibr">22</xref>]. Two-fold serial dilutions of the compound from 1024 &#x000b5;g/mL to 8 &#x000b5;g/mL (1024, 512, 256, 128, 64, 32, 16, and 8 &#x003bc;g/mL) were used. The MIC is the minimum bacteria growth inhibitory drug concentration. The positive controls (GEN or VAN) were serially diluted from 64 to 0.12 &#x000b5;g/mL. According to the results of the MIC, if the MIC was &#x0003c; 100 &#x000b5;g/mL, the compound was considered significantly active, and the compound was considered moderately active or weak if the MIC was &#x02265; 100 &#x000b5;g/mL [<xref rid="B28-molecules-28-02609" ref-type="bibr">28</xref>].</p></sec><sec id="sec4dot5-molecules-28-02609"><title>4.5. Determination of the Safety Limit of L4N</title><p>The safety limit of L4N was determined by acute oral toxicity recording (LD50 value) conducted on six groups of 6- to 8-week-old CD-1 male mice weighing 30&#x02013;40 gm (5 mice/group). The mice groups (1&#x02013;6) received 100 &#x000b5;L of 8 &#x000b5;g/mL, 16 &#x000b5;g/mL, 32 &#x000b5;g/mL, 64 &#x000b5;g/mL, 128 &#x000b5;g/mL, and 256 &#x000b5;g/mL L4N orally once daily, respectively. The mortality of the mice was recorded after 48 h [<xref rid="B33-molecules-28-02609" ref-type="bibr">33</xref>]. During the safety limit evaluation, no dead mice were observed throughout the experimental period, indicating that L4N is safe.</p></sec><sec id="sec4dot6-molecules-28-02609"><title>4.6. In Vivo Study</title><sec id="sec4dot6dot1-molecules-28-02609"><title>4.6.1. STEC O111 Oral Infection Model</title><p>A previously described oral infection model of STEC O111 was implemented [<xref rid="B34-molecules-28-02609" ref-type="bibr">34</xref>,<xref rid="B35-molecules-28-02609" ref-type="bibr">35</xref>,<xref rid="B36-molecules-28-02609" ref-type="bibr">36</xref>]. Briefly, 6- to 8-week-old CD-1 male mice weighing 30&#x02013;40 gm were divided into four groups (10 mice/group), as follows: group 1, negative control (not infected or treated), group 2, positive control (infected and not treated), group 3 (infected and then treated with L4N), and group 4 (infected and then treated with GEN). All groups were fed orally by stomach gavage with an infection dose of 100 &#x000b5;L 10<sup>8</sup> CFU of STEC O111 suspended in LB broth, except for the negative control group, which received 100 &#x000b5;L of LB broth with no bacterial cells, administered once daily for three successive days.</p></sec><sec id="sec4dot6dot2-molecules-28-02609"><title>4.6.2. <italic toggle="yes">K. pneumoniae</italic>-Sepsis-Induced Infection Model</title><p>The sepsis model was constructed as described previously, with minor modification [<xref rid="B35-molecules-28-02609" ref-type="bibr">35</xref>]. CD-1 male mice aged 6 to 8 weeks old and weighing 30&#x02013;40 gm (10 mice/group) were divided into four groups, as follows: group 1, negative control (not infected or treated), group 2, positive control (infected and not treated), group 3 (infected and then treated with L4N), and group 4 (infected and then treated with GEN). All groups were infected intraperitoneally with an infection dose of 100 &#x000b5;L 10<sup>6</sup> CFU of <italic toggle="yes">K. pneumoniae</italic> suspended in LB broth, except for the negative control group, which received100 &#x000b5;L of LB broth with no bacterial cells, administered once daily for three successive days.</p><p>After three infection days, group 3, in the case of both the STEC and <italic toggle="yes">K. pneumoniae</italic> models, received 100 &#x000b5;L of 16 &#x000b5;g/mL and 32 &#x000b5;g/mL L4N (sub-MIC concentrations), respectively for ten days, administered orally once daily. Group 4 received 33 mg/kg of GEN I.P. once daily for three successive days. The control groups received 100 &#x000b5;L of saline. The animals were fed a commercial rodent diet with free access to drinking water. The mice were divided into seven groups, each comprising six mice.</p><p>Four mice from each group were dissected, and kidneys and large intestines were isolated from cages 1, 3, 6, and 7, while lungs were isolated from cages 1, 2, 4, and 5. All organs were subjected to further histopathological examination [<xref rid="B21-molecules-28-02609" ref-type="bibr">21</xref>,<xref rid="B37-molecules-28-02609" ref-type="bibr">37</xref>]. The organs were examined and compared to the control group. They were scored according to the extent of different pathological features.</p></sec><sec id="sec4dot6dot3-molecules-28-02609"><title>4.6.3. Biochemical Parameters</title><p>Serum samples stored at &#x02212;80 &#x000b0;C were used for the measurement of the levels of tumor necrosis factor-alpha (TNF-&#x003b1;) and immunoglobulin M (IgM) using fluorescent-labelled microspheres (FluorMAP System; R&#x00026;D Systems, Wiesbaden-Nordenstadt, Germany) and the Luminex 100 instrument (Luminex BV, Oosterhout, the Netherlands). All procedures closely followed the manufacturer&#x02019;s instructions. </p></sec></sec><sec id="sec4dot7-molecules-28-02609"><title>4.7. Quantification of Bacterial Shedding</title><p>Bacterial shedding was calculated in CFU per gram of feces by plating on MacConkey agar media, as previously described [<xref rid="B38-molecules-28-02609" ref-type="bibr">38</xref>].</p><p>This procedure followed the standard method of ISO 16649-2: 2001. The preparation of test samples, initial suspension, and dilution were performed according to ISO 6887 [<xref rid="B39-molecules-28-02609" ref-type="bibr">39</xref>]. Two sterile Petri dishes were assigned for each dilution. Ten dilutions of feces from each group were prepared, and then 1 mL of each dilution was pipetted into the center of each dish. Afterwards, 15 mL of the TBX medium (44&#x02013;47 &#x000b0;C) was poured into each dish and carefully mixed with the inoculum. The mixtures were allowed to solidify at room temperature. The period (or duration) between the end of the preparation of the initial suspension (or the 10<sup>&#x02212;1</sup> dilution, if the product was a liquid) and the moment when the medium was poured into the dishes did not exceed 15 min. Finally, the dishes were inverted and incubated at 44 &#x000b0;C for 18&#x02013;24 h. The blue colonies of less than 150 CFU and less than 300 CFU in total (typical and non-typical) were counted.</p><p>The number (<italic toggle="yes">N</italic>) of <italic toggle="yes">STEC 0001</italic> per mL was calculated using the following equation:<disp-formula><italic toggle="yes">N</italic> = <italic toggle="yes">&#x003a3;<sup>c</sup></italic>/(<italic toggle="yes">n</italic><sub>1</sub> + 0.1 <italic toggle="yes">n</italic><sub>2</sub>)<italic toggle="yes">d</italic></disp-formula></p><p>Here, <italic toggle="yes">&#x003a3;<sup>c</sup></italic> is the sum of the characteristic colonies counted on all the dishes retained, <italic toggle="yes">n<sub>1</sub></italic> is the number of dishes retained in the first dilution, <italic toggle="yes">n<sub>2</sub></italic> is the number of dishes retained in the last dilution, and <italic toggle="yes">d</italic> is the dilution factor corresponding to the first dilution.</p></sec><sec id="sec4dot8-molecules-28-02609"><title>4.8. Statistics</title><p>All quantitative results were analyzed using SPSS version 17.0 for Windows. Data are presented as the mean &#x000b1; SD. Comparisons between multiple group means were performed using a one-way analysis of variance. Statistical significance was set as <italic toggle="yes">p</italic> &#x02264; 0.05.</p></sec></sec><sec sec-type="conclusions" id="sec5-molecules-28-02609"><title>5. Conclusions</title><p>It can be concluded that flavonoid-rich plants are good candidates for the treatment of MDR infections. This study presented luteolin 4&#x02032;-neohesperidoside as a potent substitute for traditional antibiotics, as it showed anti-STEC O111 and anti-<italic toggle="yes">K. pneumoniae</italic> activities. This was confirmed by the observed reduction in the levels of pro-inflammatory markers and immunoglobulin, with a parallel improvement upon histopathological examination of renal and pulmonary lesions, which were remarkably enhanced, as well as a significant lowering of the bacterial loads in tissues.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to express thanks for the funding received through the Researchers Supporting Project (number RSP2023R497), funded by the King Saud University, Riyadh, Saudi Arabia.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>R.A.E.-S. and R.E.: study design, methodology, investigation and writing of the manuscript. M.A.E., I.A.N. and S.I.B.: supervision, critical reading of the manuscript and funding of the work. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All animal experiments were performed in accordance with the Faculty of Pharmacy-Ahram Canadian University Research Ethics committee, Faculty of Pharmacy, Ahram Canadian University, Egypt (REC0922). The date of approval was 20 December 2022.</p></notes><notes><title>Informed Consent Statement</title><p>Not acceptable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not acceptable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><notes><title>Sample Availability</title><p>Samples of the compound (L4N) are available upon request from the authors.</p></notes><ref-list><title>References</title><ref id="B1-molecules-28-02609"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murray</surname><given-names>C.J.</given-names></name>
<name><surname>Ikuta</surname><given-names>K.S.</given-names></name>
<name><surname>Sharara</surname><given-names>F.</given-names></name>
<name><surname>Swetschinski</surname><given-names>L.</given-names></name>
<name><surname>Aguilar</surname><given-names>G.R.</given-names></name>
<name><surname>Gray</surname><given-names>A.</given-names></name>
<name><surname>Han</surname><given-names>C.</given-names></name>
<name><surname>Bisignano</surname><given-names>C.</given-names></name>
<name><surname>Rao</surname><given-names>P.</given-names></name>
<name><surname>Wool</surname><given-names>E.</given-names></name>
</person-group><article-title>Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id>
</element-citation></ref><ref id="B2-molecules-28-02609"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alhadrami</surname><given-names>H.A.</given-names></name>
<name><surname>Hamed</surname><given-names>A.A.</given-names></name>
<name><surname>Hassan</surname><given-names>H.M.</given-names></name>
<name><surname>Belbahri</surname><given-names>L.</given-names></name>
<name><surname>Rateb</surname><given-names>M.E.</given-names></name>
<name><surname>Sayed</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Flavonoids as potential anti-MRSA agents through modulation of PBP2a: A computational and experimental study</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><elocation-id>562</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9090562</pub-id><pub-id pub-id-type="pmid">32878266</pub-id>
</element-citation></ref><ref id="B3-molecules-28-02609"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shamsudin</surname><given-names>N.F.</given-names></name>
<name><surname>Ahmed</surname><given-names>Q.U.</given-names></name>
<name><surname>Mahmood</surname><given-names>S.</given-names></name>
<name><surname>Ali Shah</surname><given-names>S.A.</given-names></name>
<name><surname>Khatib</surname><given-names>A.</given-names></name>
<name><surname>Mukhtar</surname><given-names>S.</given-names></name>
<name><surname>Alsharif</surname><given-names>M.A.</given-names></name>
<name><surname>Parveen</surname><given-names>H.</given-names></name>
<name><surname>Zakaria</surname><given-names>Z.A.</given-names></name>
</person-group><article-title>Antibacterial Effects of Flavonoids and Their Structure-Activity Relationship Study: A Comparative Interpretation</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1149</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27041149</pub-id><pub-id pub-id-type="pmid">35208939</pub-id>
</element-citation></ref><ref id="B4-molecules-28-02609"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kokoska</surname><given-names>L.</given-names></name>
<name><surname>Kloucek</surname><given-names>P.</given-names></name>
<name><surname>Leuner</surname><given-names>O.</given-names></name>
<name><surname>Novy</surname><given-names>P.</given-names></name>
</person-group><article-title>Plant-derived products as antibacterial and antifungal agents in human health care</article-title><source>Curr. Med. Chem.</source><year>2019</year><volume>26</volume><fpage>5501</fpage><lpage>5541</lpage><pub-id pub-id-type="doi">10.2174/0929867325666180831144344</pub-id><pub-id pub-id-type="pmid">30182844</pub-id>
</element-citation></ref><ref id="B5-molecules-28-02609"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Pandey</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Chemistry and biological activities of flavonoids: An overview</article-title><source>Sci. World J.</source><year>2013</year><volume>2013</volume><fpage>162750</fpage><pub-id pub-id-type="doi">10.1155/2013/162750</pub-id><pub-id pub-id-type="pmid">24470791</pub-id>
</element-citation></ref><ref id="B6-molecules-28-02609"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amin</surname><given-names>M.U.</given-names></name>
<name><surname>Khurram</surname><given-names>M.</given-names></name>
<name><surname>Khattak</surname><given-names>B.</given-names></name>
<name><surname>Khan</surname><given-names>J.</given-names></name>
</person-group><article-title>Antibiotic additive and synergistic action of rutin, morin and quercetin against methicillin resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>BMC Complement. Altern. Med.</source><year>2015</year><volume>15</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-015-0580-0</pub-id><pub-id pub-id-type="pmid">25879586</pub-id>
</element-citation></ref><ref id="B7-molecules-28-02609"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cushnie</surname><given-names>T.T.</given-names></name>
<name><surname>Lamb</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Antimicrobial activity of flavonoids</article-title><source>Int. J. Antimicrob. Agents</source><year>2005</year><volume>26</volume><fpage>343</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2005.09.002</pub-id><pub-id pub-id-type="pmid">16323269</pub-id>
</element-citation></ref><ref id="B8-molecules-28-02609"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farhadi</surname><given-names>F.</given-names></name>
<name><surname>Khameneh</surname><given-names>B.</given-names></name>
<name><surname>Iranshahi</surname><given-names>M.</given-names></name>
<name><surname>Iranshahy</surname><given-names>M.</given-names></name>
</person-group><article-title>Antibacterial activity of flavonoids and their structure&#x02013;activity relationship: An update review</article-title><source>Phytother. Res.</source><year>2019</year><volume>33</volume><fpage>13</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/ptr.6208</pub-id><pub-id pub-id-type="pmid">30346068</pub-id>
</element-citation></ref><ref id="B9-molecules-28-02609"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramesh</surname><given-names>M.</given-names></name>
<name><surname>Rao</surname><given-names>Y.N.</given-names></name>
<name><surname>Rao</surname><given-names>A.A.</given-names></name>
<name><surname>Prabhakar</surname><given-names>M.</given-names></name>
<name><surname>Rao</surname><given-names>C.S.</given-names></name>
<name><surname>Muralidhar</surname><given-names>N.</given-names></name>
<name><surname>Reddy</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Antinociceptive and anti-inflammatory activity of a flavonoid isolated from <italic toggle="yes">Caralluma attenuata</italic></article-title><source>J. Ethnopharmacol.</source><year>1998</year><volume>62</volume><fpage>63</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S0378-8741(98)00048-8</pub-id><pub-id pub-id-type="pmid">9720613</pub-id>
</element-citation></ref><ref id="B10-molecules-28-02609"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Shiekh</surname><given-names>R.A.</given-names></name>
<name><surname>Hassan</surname><given-names>M.</given-names></name>
<name><surname>Hashem</surname><given-names>R.A.</given-names></name>
<name><surname>Abdel-Sattar</surname><given-names>E.</given-names></name>
</person-group><article-title>Bioguided isolation of antibiofilm and antibacterial pregnane glycosides from <italic toggle="yes">Caralluma quadrangula</italic>: Disarming multidrug-resistant pathogens</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>811</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10070811</pub-id><pub-id pub-id-type="pmid">34356732</pub-id>
</element-citation></ref><ref id="B11-molecules-28-02609"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Ding</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>Y.T.</given-names></name>
<name><surname>Cheng</surname><given-names>C.</given-names></name>
<name><surname>Shan</surname><given-names>W.S.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>W.</given-names></name>
</person-group><article-title>Scutellarin ameliorates cartilage degeneration in osteoarthritis by inhibiting the Wnt/&#x003b2;-catenin and MAPK signaling pathways</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>78</volume><fpage>105954</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.105954</pub-id><pub-id pub-id-type="pmid">31757676</pub-id>
</element-citation></ref><ref id="B12-molecules-28-02609"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biharee</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Jaitak</surname><given-names>V.</given-names></name>
</person-group><article-title>Antimicrobial flavonoids as a potential substitute for overcoming antimicrobial resistance</article-title><source>Fitoterapia</source><year>2020</year><volume>146</volume><fpage>104720</fpage><pub-id pub-id-type="doi">10.1016/j.fitote.2020.104720</pub-id><pub-id pub-id-type="pmid">32910994</pub-id>
</element-citation></ref><ref id="B13-molecules-28-02609"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>L.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>Antibacterial modes of herbal flavonoids combat resistant bacteria</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><fpage>2122</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.873374</pub-id></element-citation></ref><ref id="B14-molecules-28-02609"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pereira</surname><given-names>R.V.</given-names></name>
<name><surname>Mecenas</surname><given-names>A.S.</given-names></name>
<name><surname>Malafaia</surname><given-names>C.R.A.</given-names></name>
<name><surname>Amaral</surname><given-names>A.C.F.</given-names></name>
<name><surname>Muzitano</surname><given-names>M.F.</given-names></name>
<name><surname>Simas</surname><given-names>N.K.</given-names></name>
<name><surname>Correa Ramos Leal</surname><given-names>I.</given-names></name>
</person-group><article-title>Evaluation of the chemical composition and antioxidant activity of extracts and fractions of <italic toggle="yes">Ocotea notata</italic> (Ness) Mez (Lauraceae)</article-title><source>Nat. Prod. Res.</source><year>2020</year><volume>34</volume><fpage>3004</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1080/14786419.2019.1602828</pub-id><pub-id pub-id-type="pmid">30990334</pub-id>
</element-citation></ref><ref id="B15-molecules-28-02609"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pruteanu</surname><given-names>M.</given-names></name>
<name><surname>Hern&#x000e1;ndez Lobato</surname><given-names>J.I.</given-names></name>
<name><surname>Stach</surname><given-names>T.</given-names></name>
<name><surname>Hengge</surname><given-names>R.</given-names></name>
</person-group><article-title>Common plant flavonoids prevent the assembly of amyloid curli fibres and can interfere with bacterial biofilm formation</article-title><source>Environ. Microbiol.</source><year>2020</year><volume>22</volume><fpage>5280</fpage><lpage>5299</lpage><pub-id pub-id-type="doi">10.1111/1462-2920.15216</pub-id><pub-id pub-id-type="pmid">32869465</pub-id>
</element-citation></ref><ref id="B16-molecules-28-02609"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dos Santos</surname><given-names>C.</given-names></name>
<name><surname>Dos Santos</surname><given-names>L.S.</given-names></name>
<name><surname>Franco</surname><given-names>O.L.</given-names></name>
</person-group><article-title>Fosfomycin and nitrofurantoin: Classic antibiotics and perspectives</article-title><source>J. Antibiot.</source><year>2021</year><volume>74</volume><fpage>547</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41429-021-00444-z</pub-id></element-citation></ref><ref id="B17-molecules-28-02609"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaye</surname><given-names>K.S.</given-names></name>
<name><surname>Rice</surname><given-names>L.B.</given-names></name>
<name><surname>Dane</surname><given-names>A.L.</given-names></name>
<name><surname>Stus</surname><given-names>V.</given-names></name>
<name><surname>Sagan</surname><given-names>O.</given-names></name>
<name><surname>Fedosiuk</surname><given-names>E.</given-names></name>
<name><surname>Das</surname><given-names>A.F.</given-names></name>
<name><surname>Skarinsky</surname><given-names>D.</given-names></name>
<name><surname>Eckburg</surname><given-names>P.B.</given-names></name>
<name><surname>Ellis-Grosse</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 randomized trial</article-title><source>Clin. Infect. Dis.</source><year>2019</year><volume>69</volume><fpage>2045</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz181</pub-id><pub-id pub-id-type="pmid">30861061</pub-id>
</element-citation></ref><ref id="B18-molecules-28-02609"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amladi</surname><given-names>A.U.</given-names></name>
<name><surname>Abirami</surname><given-names>B.</given-names></name>
<name><surname>Devi</surname><given-names>S.M.</given-names></name>
<name><surname>Sudarsanam</surname><given-names>T.D.</given-names></name>
<name><surname>Kandasamy</surname><given-names>S.</given-names></name>
<name><surname>Kekre</surname><given-names>N.</given-names></name>
<name><surname>Veeraraghavan</surname><given-names>B.</given-names></name>
<name><surname>Sahni</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Susceptibility profile, resistance mechanisms &#x00026; efficacy ratios of fosfomycin, nitrofurantoin &#x00026; colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections</article-title><source>Indian J. Med. Res.</source><year>2019</year><volume>149</volume><fpage>185</fpage><pub-id pub-id-type="pmid">31219082</pub-id>
</element-citation></ref><ref id="B19-molecules-28-02609"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rizwani</surname><given-names>G.H.</given-names></name>
<name><surname>Usmanghani</surname><given-names>K.</given-names></name>
<name><surname>Ahmad</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>V.</given-names></name>
</person-group><article-title>Flavone glycosides of <italic toggle="yes">Caralluma tuberculata</italic> NE Brown</article-title><source>Pak. J. Pharm. Sci.</source><year>1990</year><volume>3</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16414667</pub-id>
</element-citation></ref><ref id="B20-molecules-28-02609"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Usman Amin</surname><given-names>M.</given-names></name>
<name><surname>Khurram</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>T.A.</given-names></name>
<name><surname>Faidah</surname><given-names>H.S.</given-names></name>
<name><surname>Ullah Shah</surname><given-names>Z.</given-names></name>
<name><surname>Ur Rahman</surname><given-names>S.</given-names></name>
<name><surname>Haseeb</surname><given-names>A.</given-names></name>
<name><surname>Ilyas</surname><given-names>M.</given-names></name>
<name><surname>Ullah</surname><given-names>N.</given-names></name>
<name><surname>Umar Khayam</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Effects of luteolin and quercetin in combination with some conventional antibiotics against methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>1947</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17111947</pub-id><pub-id pub-id-type="pmid">27879665</pub-id>
</element-citation></ref><ref id="B21-molecules-28-02609"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eloutify</surname><given-names>Y.T.</given-names></name>
<name><surname>El-Shiekh</surname><given-names>R.A.</given-names></name>
<name><surname>Ibrahim</surname><given-names>K.M.</given-names></name>
<name><surname>Elshimy</surname><given-names>R.</given-names></name>
<name><surname>Avula</surname><given-names>B.</given-names></name>
<name><surname>Katragunta</surname><given-names>K.</given-names></name>
<name><surname>Khan</surname><given-names>I.</given-names></name>
<name><surname>Meselhy</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Bioassay-guided isolation of Antimicrobial Components and LC/QToF Profile of <italic toggle="yes">Plumeria obtusa</italic>: Potential for the treatment of Antimicrobial Resistance</article-title><source>ACS Omega</source><year>2023</year><volume>8</volume><fpage>6476</fpage><lpage>6491</lpage><pub-id pub-id-type="doi">10.1021/acsomega.2c06803</pub-id><pub-id pub-id-type="pmid">36844537</pub-id>
</element-citation></ref><ref id="B22-molecules-28-02609"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Freitas</surname><given-names>L.C.</given-names></name>
<name><surname>de Sordi</surname><given-names>M.R.L.</given-names></name>
<name><surname>Malavasi</surname><given-names>M.M.S.</given-names></name>
<name><surname>de Freitas</surname><given-names>H.C.L.</given-names></name>
</person-group><source>Avalia&#x000e7;&#x000e3;o Educacional: Caminhando pela Contram&#x000e3;o</source><publisher-name>Editora Vozes Limitada</publisher-name><publisher-loc>Curitiba, Brazil</publisher-loc><year>2017</year></element-citation></ref><ref id="B23-molecules-28-02609"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elshimy</surname><given-names>R.</given-names></name>
<name><surname>Zedan</surname><given-names>H.</given-names></name>
<name><surname>Elmorsy</surname><given-names>T.H.</given-names></name>
<name><surname>Khattab</surname><given-names>R.A.</given-names></name>
</person-group><article-title>A Study on Multidrug-Resistant Escherichia coli Clinical Isolates from Different Hospitals in Greater Cairo</article-title><source>Microb. Drug Resist.</source><year>2021</year><volume>27</volume><fpage>1420</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1089/mdr.2020.0521</pub-id><pub-id pub-id-type="pmid">34042527</pub-id>
</element-citation></ref><ref id="B24-molecules-28-02609"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Basile</surname><given-names>A.</given-names></name>
<name><surname>Giordano</surname><given-names>S.</given-names></name>
<name><surname>L&#x000f3;pez-S&#x000e1;ez</surname><given-names>J.A.</given-names></name>
<name><surname>Cobianchi</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Antibacterial activity of pure flavonoids isolated from mosses</article-title><source>Phytochemistry</source><year>1999</year><volume>52</volume><fpage>1479</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(99)00286-1</pub-id><pub-id pub-id-type="pmid">10647220</pub-id>
</element-citation></ref><ref id="B25-molecules-28-02609"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Wayne</surname><given-names>P.</given-names></name>
</person-group><article-title>Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Susceptibility Testing</article-title><source>CLSI Supplement M100S</source><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B26-molecules-28-02609"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rana</surname><given-names>E.</given-names></name>
<name><surname>Rania</surname><given-names>A.K.</given-names></name>
<name><surname>Hamdallah</surname><given-names>Z.</given-names></name>
<name><surname>Alaa</surname><given-names>E.-D.S.H.</given-names></name>
<name><surname>Tarek</surname><given-names>H.E.</given-names></name>
</person-group><article-title>Study on prevalence and genetic discrimination of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) in Egyptian hospitals</article-title><source>Afr. J. Microbiol. Res.</source><year>2018</year><volume>12</volume><fpage>629</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.5897/AJMR2017.8742</pub-id></element-citation></ref><ref id="B27-molecules-28-02609"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajapaksha</surname><given-names>P.</given-names></name>
<name><surname>Elbourne</surname><given-names>A.</given-names></name>
<name><surname>Gangadoo</surname><given-names>S.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names></name>
<name><surname>Cozzolino</surname><given-names>D.</given-names></name>
<name><surname>Chapman</surname><given-names>J.</given-names></name>
</person-group><article-title>A review of methods for the detection of pathogenic microorganisms</article-title><source>Analyst</source><year>2019</year><volume>144</volume><fpage>396</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1039/C8AN01488D</pub-id><pub-id pub-id-type="pmid">30468217</pub-id>
</element-citation></ref><ref id="B28-molecules-28-02609"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabino-Silva</surname><given-names>R.</given-names></name>
<name><surname>Jardim</surname><given-names>A.C.G.</given-names></name>
<name><surname>Siqueira</surname><given-names>W.L.</given-names></name>
</person-group><article-title>Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis</article-title><source>Clin. Oral Investig.</source><year>2020</year><volume>24</volume><fpage>1619</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1007/s00784-020-03248-x</pub-id></element-citation></ref><ref id="B29-molecules-28-02609"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>A.</given-names></name>
</person-group><article-title>Antibiotic susceptibility testing by a standardized single disc method</article-title><source>Am. J. Clin. Pathol.</source><year>1966</year><volume>45</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1093/ajcp/45.4_ts.493</pub-id></element-citation></ref><ref id="B30-molecules-28-02609"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Purkait</surname><given-names>S.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>A.</given-names></name>
<name><surname>Bag</surname><given-names>A.</given-names></name>
<name><surname>Chattopadhyay</surname><given-names>R.</given-names></name>
</person-group><article-title>Synergistic antibacterial, antifungal and antioxidant efficacy of cinnamon and clove essential oils in combination</article-title><source>Arch. Microbiol.</source><year>2020</year><volume>202</volume><fpage>1439</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1007/s00203-020-01858-3</pub-id><pub-id pub-id-type="pmid">32185411</pub-id>
</element-citation></ref><ref id="B31-molecules-28-02609"><label>31.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Wayne</surname><given-names>P.</given-names></name>
</person-group><source>Performance Standards for Antimicrobial Susceptibility Testing</source><publisher-name>Ninth Informational Clinical and Laboratory Standard Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2008</year></element-citation></ref><ref id="B32-molecules-28-02609"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Wayne</surname><given-names>P.</given-names></name>
</person-group><source>Performance Standards for Antimicrobial Susceptibility Testing</source><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2011</year></element-citation></ref><ref id="B33-molecules-28-02609"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Regupathy</surname><given-names>A.</given-names></name>
<name><surname>Dhamu</surname><given-names>K.</given-names></name>
</person-group><source>Statistics Work Book for Insecticide Toxicology</source><publisher-name>Suriya Desktop Publishers</publisher-name><publisher-loc>Kathmandu, Nepal</publisher-loc><year>1990</year></element-citation></ref><ref id="B34-molecules-28-02609"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Myhal</surname><given-names>M.</given-names></name>
<name><surname>Laux</surname><given-names>D.</given-names></name>
<name><surname>Cohen</surname><given-names>P.</given-names></name>
</person-group><article-title>Relative colonizing abilities of human fecal and K 12 strains of <italic toggle="yes">Escherichia coli</italic> in the large intestines of streptomycin-treated mice</article-title><source>Eur. J. Clin. Microbiol.</source><year>1982</year><volume>1</volume><fpage>186</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/BF02019621</pub-id><pub-id pub-id-type="pmid">6756909</pub-id>
</element-citation></ref><ref id="B35-molecules-28-02609"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toledo</surname><given-names>P.V.M.</given-names></name>
<name><surname>Aranha Junior</surname><given-names>A.A.</given-names></name>
<name><surname>Arend</surname><given-names>L.N.</given-names></name>
<name><surname>Ribeiro</surname><given-names>V.</given-names></name>
<name><surname>Zavascki</surname><given-names>A.P.</given-names></name>
<name><surname>Tuon</surname><given-names>F.F.</given-names></name>
</person-group><article-title>Activity of antimicrobial combinations against KPC-2-producing <italic toggle="yes">Klebsiella pneumoniae</italic> in a rat model and time-kill assay</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>4301</fpage><lpage>4304</lpage><pub-id pub-id-type="doi">10.1128/AAC.00323-15</pub-id><pub-id pub-id-type="pmid">25896686</pub-id>
</element-citation></ref><ref id="B36-molecules-28-02609"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseinzadeh</surname><given-names>H.</given-names></name>
<name><surname>Fazly Bazzaz</surname><given-names>B.</given-names></name>
<name><surname>Haghi</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Antibacterial activity of total extracts and essential oil of <italic toggle="yes">Nigella sativa</italic> L. seeds in mice</article-title><source>Pharmacologyonline</source><year>2007</year><volume>2</volume><fpage>429</fpage><lpage>435</lpage></element-citation></ref><ref id="B37-molecules-28-02609"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bancroft</surname><given-names>J.</given-names></name>
<name><surname>Suvarna</surname><given-names>S.</given-names></name>
<name><surname>Layton</surname><given-names>C.</given-names></name>
</person-group><source>Bancroft&#x02019;s Theory and Practice of Histological Techniques</source><edition>7th ed.</edition><publisher-name>British, Churchill Livingstone Elsevier Ltd.</publisher-name><publisher-loc>London, UK</publisher-loc><year>2013</year></element-citation></ref><ref id="B38-molecules-28-02609"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>T.M.</given-names></name>
<name><surname>Bray</surname><given-names>A.S.</given-names></name>
<name><surname>Nagpal</surname><given-names>R.K.</given-names></name>
<name><surname>Caudell</surname><given-names>D.L.</given-names></name>
<name><surname>Yadav</surname><given-names>H.</given-names></name>
<name><surname>Zafar</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Animal model to study <italic toggle="yes">Klebsiella pneumoniae</italic> gastrointestinal colonization and host-to-host transmission</article-title><source>Infect. Immun.</source><year>2020</year><volume>88</volume><fpage>e00071-20</fpage><pub-id pub-id-type="doi">10.1128/IAI.00071-20</pub-id><pub-id pub-id-type="pmid">32839189</pub-id>
</element-citation></ref><ref id="B39-molecules-28-02609"><label>39.</label><element-citation publication-type="book"><std>ISO 6887-3:2003</std><source>Microbiology of Food and Feed&#x02014;Preparation of Samples, Initial Suspension and Dilutions for Microbiological Examination&#x02014;Part 3: Specific Rules for the Preparation of Fish and Fishery Products</source><publisher-name>International Standards Organisation</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2003</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="molecules-28-02609-f001"><label>Figure 1</label><caption><p>Structure of luteolin 4&#x02032;-neohesperidoside (L4N).</p></caption><graphic xlink:href="molecules-28-02609-g001" position="float"/></fig><fig position="float" id="molecules-28-02609-f002"><label>Figure 2</label><caption><p>Inhibition zones of D: DMSO for 1: luteolin 4&#x02032;-neohesperidoside (L4N) alone, 2: penicillin combined with L4N, 3: vancomycin alone, and 4: vancomycin combined with L4N.</p></caption><graphic xlink:href="molecules-28-02609-g002" position="float"/></fig><fig position="float" id="molecules-28-02609-f003"><label>Figure 3</label><caption><p>Tumor necrosis factor-alpha (TNF-&#x003b1;, pg/mL) levels in mice infected with MDR <italic toggle="yes">K. pneumoniae</italic> (<bold>A</bold>) and <italic toggle="yes">E. coli</italic> O111 (<bold>B</bold>) and then treated with luteolin 4&#x02032;-neohesperidoside (L4N) and gentamycin (GEN). <sup>a</sup> Significant difference from normal control group at <italic toggle="yes">p</italic> &#x0003c; 0.05. <sup>b</sup> Significant difference from infected group at <italic toggle="yes">p</italic> &#x0003c; 0.05. <sup>ab</sup> Significant difference from normal control group and infected group at <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="molecules-28-02609-g003" position="float"/></fig><fig position="float" id="molecules-28-02609-f004"><label>Figure 4</label><caption><p>Immunoglobulin M (IgM, ng/mL) levels in the model of mice infected with MDR <italic toggle="yes">K. pneumoniae</italic> (<bold>A</bold>) and <italic toggle="yes">E. coli</italic> STEC O111 (<bold>B</bold>) and then treated with luteolin 4&#x02032;-neohesperidoside (L4N) and gentamycin (GEN). <sup>a</sup> Significant difference from normal control group at <italic toggle="yes">p</italic> &#x0003c; 0.05. <sup>b</sup> Significant difference from infected group at <italic toggle="yes">p</italic> &#x0003c; 0.05. <sup>ab</sup> Significant difference from normal control group and infected group at <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="molecules-28-02609-g004" position="float"/></fig><fig position="float" id="molecules-28-02609-f005"><label>Figure 5</label><caption><p>Histological sections of lungs stained with H&#x00026;E and scoring of pulmonary lesions in a model of mice infected with MDR <italic toggle="yes">K. pneumoniae</italic>. (<bold>a</bold>) Mice infected with <italic toggle="yes">K. pneumoniae</italic> (X = 400), (<bold>b</bold>) mice infected with <italic toggle="yes">K. pneumoniae</italic> and then treated with gentamycin (GEN) (X = 200) [<xref rid="B21-molecules-28-02609" ref-type="bibr">21</xref>], and (<bold>c</bold>) mice infected with <italic toggle="yes">K. pneumoniae</italic> and then treated with luteolin 4&#x02032;-neohesperidoside (L4N) (X = 200).</p></caption><graphic xlink:href="molecules-28-02609-g005" position="float"/></fig><fig position="float" id="molecules-28-02609-f006"><label>Figure 6</label><caption><p>Histological sections of kidneys stained with H&#x00026;E and scoring of renal lesions in a model of mice infected with <italic toggle="yes">E. coli</italic> O111. (<bold>a</bold>) Mice infected with <italic toggle="yes">E. coli</italic> O111 (X = 200), (<bold>b</bold>) mice infected with <italic toggle="yes">E. coli</italic> O111 and then treated with gentamycin (GEN) (X = 200), and (<bold>c</bold>) mice infected with <italic toggle="yes">E. coli</italic> O111 and then treated with luteolin 4&#x02032;-neohesperidoside (L4N) (X = 200).</p></caption><graphic xlink:href="molecules-28-02609-g006" position="float"/></fig><fig position="float" id="molecules-28-02609-f007"><label>Figure 7</label><caption><p>Quantification of STEC O111 on TBX media.</p></caption><graphic xlink:href="molecules-28-02609-g007" position="float"/></fig><fig position="float" id="molecules-28-02609-f008"><label>Figure 8</label><caption><p>Quantification of <italic toggle="yes">K. pneumoniae</italic> on MacConkey agar media.</p></caption><graphic xlink:href="molecules-28-02609-g008" position="float"/></fig><table-wrap position="float" id="molecules-28-02609-t001"><object-id pub-id-type="pii">molecules-28-02609-t001_Table 1</object-id><label>Table 1</label><caption><p>Inhibition zones of antibiotics and luteolin 4&#x02032;-neohesperidoside (L4N) in regard to MDR Gram-negative bacteria (STEC O111 and MDR <italic toggle="yes">K. pneumoniae</italic>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Test Agent</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Zone of Inhibition<break/>(Mean &#x000b1; SD) (mm)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STEC O111</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDR <italic toggle="yes">K. pneumonia</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">DMSO</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AK</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GEN</td><td align="center" valign="middle" rowspan="1" colspan="1">17.0 &#x000b1; 1.00 <sup>b</sup> (S)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.66 &#x000b1; 0.57 <sup>b</sup> (R)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L4N</td><td align="center" valign="middle" rowspan="1" colspan="1">20.6 &#x000b1; 2.08 <sup>c</sup> (S)</td><td align="center" valign="middle" rowspan="1" colspan="1">18.00 &#x000b1; 0.0 <sup>c</sup> (S)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AK + L4N</td><td align="center" valign="middle" rowspan="1" colspan="1">18.0 &#x000b1; 0.0 <sup>b</sup> (S)</td><td align="center" valign="middle" rowspan="1" colspan="1">18.66 &#x000b1; 1.15 <sup>c</sup> (S)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GEN + L4N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.0 &#x000b1; 1.00 <sup>c</sup> (S)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.00 &#x000b1; 0.0 <sup>d</sup> (I)</td></tr></tbody></table><table-wrap-foot><fn><p>DMSO: dimethyl sulfoxide (negative control), AK: amikacin, GEN: gentamycin, R: resistant, S: sensitive, I: intermediate, L4N: luteolin 4&#x02032;-neohesperidoside. There are significant differences between means with different letters at <italic toggle="yes">p</italic> &#x02264; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-28-02609-t002"><object-id pub-id-type="pii">molecules-28-02609-t002_Table 2</object-id><label>Table 2</label><caption><p>Inhibition zones of antibiotics and luteolin 4&#x02032;-neohesperidoside (L4N) in regard to MDR Gram-positive bacteria (MRSA and MDR <italic toggle="yes">B. cereus</italic>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Zone of Inhibition<break/>(Mean &#x000b1; SD)<break/>mm</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">B. cereus</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">DMSO</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PEN</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup> (R)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VAN</td><td align="center" valign="middle" rowspan="1" colspan="1">8.66 &#x000b1; 0.57 <sup>b</sup> (R)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.66 &#x000b1; 0.57 <sup>b</sup> (S)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L4N</td><td align="center" valign="middle" rowspan="1" colspan="1">6.0 &#x000b1; 1.0 <sup>c</sup> (R)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.0 &#x000b1; 0 <sup>c</sup> (S)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PEN + L4N</td><td align="center" valign="middle" rowspan="1" colspan="1">5.66 &#x000b1; 0.57 <sup>c</sup> (R)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.0 &#x000b1; 0 <sup>b</sup> (I)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAN + L4N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.66 &#x000b1; 1.52 <sup>d</sup> (S)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.0 &#x000b1; 1 <sup>d</sup> (S)</td></tr></tbody></table><table-wrap-foot><fn><p>DMSO: dimethyl sulfoxide (negative contro), R: resistant, S: sensitive, I: intermediate, PEN: penicillin, L4N: luteolin 4&#x02032;-neohesperidoside, VAN: vancomycin. There are significant differences between means with different letters at <italic toggle="yes">p</italic> &#x02264; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-28-02609-t003"><object-id pub-id-type="pii">molecules-28-02609-t003_Table 3</object-id><label>Table 3</label><caption><p>MIC of luteolin 4&#x02032;-neohesperidoside (L4N) against MDR <italic toggle="yes">E. coli</italic> O 111 and MDR <italic toggle="yes">K. pneumoniae</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MIC (&#x000b5;g/mL)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STEC O111</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDR <italic toggle="yes">K. pneumoniae</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NC</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L4N</td><td align="center" valign="middle" rowspan="1" colspan="1">26.66 &#x000b1; 5.23 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">53.33 &#x000b1; 8.47 <sup>c</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GEN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.00 &#x000b1; 0 <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.66 &#x000b1; 1.15 <sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn><p>NC: negative control (plain media agar extracts in 0.2% DMSO), GEN: gentamycin, LN: luteolin 4&#x02032;-neohesperidoside. There are significant differences between means with different letters at <italic toggle="yes">p</italic> &#x02264; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-28-02609-t004"><object-id pub-id-type="pii">molecules-28-02609-t004_Table 4</object-id><label>Table 4</label><caption><p>MIC of luteolin 4&#x02032;-neohesperidoside (L4N) against MRSA and B. cereus.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">MIC (&#x003bc;g/mL)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDR <italic toggle="yes">B. cereus</italic></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NC</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.0 &#x000b1; 0.0 <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">L4N</td><td align="center" valign="middle" rowspan="1" colspan="1">106.66 &#x000b1; 6.95 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">213.33 &#x000b1; 7.9 <sup>c</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VAN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.00 &#x000b1; 0 <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0 &#x000b1; 0 <sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn><p>NC: negative control (plain media agar extracts in 0.2% DMSO), VAN: vancomycin, LN: luteolin 4&#x02032;-neohesperidoside. There are significant differences between means with different letters at <italic toggle="yes">p</italic> &#x02264; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-28-02609-t005"><object-id pub-id-type="pii">molecules-28-02609-t005_Table 5</object-id><label>Table 5</label><caption><p>Scoring of pulmonary lesions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">a</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">b</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">c</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">d</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Hemorrhage</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Thickened interalveolar septa</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>RBCs in alveolar lamina</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Perivascular oedema</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>a = negative control, b = positive control, c = treatment with luteolin 4&#x02032;-neohesperidoside (L4N), d = treatment with gentamycin (GEN).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-28-02609-t006"><object-id pub-id-type="pii">molecules-28-02609-t006_Table 6</object-id><label>Table 6</label><caption><p>Scoring of renal lesions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">a</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">b</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">c</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">d</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Subcapsular hemorrhage</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Interstitial hemorrhage</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Necrobiotic changes in tubular epithelium</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Interstitial inflammatory cell infiltration</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Renal cast</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>a = negative control, b = positive control, c = treatment with luteolin 4&#x02032;-neohesperidoside (L4N), d = treatment with gentamycin (GEN).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-28-02609-t007"><object-id pub-id-type="pii">molecules-28-02609-t007_Table 7</object-id><label>Table 7</label><caption><p>Quantification of bacterial loads of STEC O111 and <italic toggle="yes">K. pneumoniae</italic> shed in the feces and bacterial colonization in the kidneys and lungs.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</td><td colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>STEC O111 (CFU/g Feces)</bold>
</td><td colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>
<italic toggle="yes">K. pneumoniae</italic> (CFU/g Feces)
</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Negative Control</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Positive Control STEC O111</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>STEC O111 then L4N</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>STEC O111 then GEN</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Negative Control</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Positive Control <italic toggle="yes">K. pneumoniae</italic></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">K. pneumoniae</italic> then L4N</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">K. pneumoniae</italic> then GEN</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day zero</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#x000d7; 10<sup>4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 &#x000d7; 10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000d7; 10<sup>4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000d7; 10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 &#x000d7; 10<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 &#x000d7; 10<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 &#x000d7; 10<sup>2</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 4 (before challenge and after treatment with streptomycin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000d7; 10<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000d7; 10<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000d7; 10<sup>1</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 7 (after challenge)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x000d7; 10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 &#x000d7; 10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 &#x000d7; 10<sup>6</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 10 (after treatment, 3 successive days of treatment with GEN I.P. once daily)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x000d7; 10<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#x000d7; 10<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 &#x000d7; 10<sup>4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;250 &#x000d7; 10<sup>2</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Day 17 (after treatment, 7 successive days of treatment with LN I.P. once daily)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 &#x000d7; 10<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#x000d7; 10<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kidney</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x000d7; 10<sup>1</sup></td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;300 &#x000d7; 10<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#x000d7; 10<sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 &#x000d7; 10<sup>2</sup></td></tr></tbody></table><table-wrap-foot><fn><p>CFU: colony-forming unit, GEN: gentamycin, NA: not applicable, L4N: luteolin 4&#x02032;-neohesperidoside.</p></fn></table-wrap-foot></table-wrap></floats-group></article>